Blocking Fragment of CDCP1

Tech ID: 29113 / UC Case 2018-064-0

Brief Description

Triple-negative breast cancer (TNBC) refers to any breast cancer that does not express the genes for estrogen receptor (ER), progesterone receptor (PR) or Her2/neu. TNBC is difficult to treat since most hormone therapies target one of these receptors. Researchers at UCI have developed a therapeutic that bypasses these receptors, and instead targets fatty acid oxidation, a process linked to TNBC.

Full Description

Triple-negative breast cancer (TNBC) refers to any breast cancer that does not express the genes for estrogen receptor (ER), progesterone receptor (PR) or Her2/neu. There are currently no targeted therapies to treat TNBC and approximately 34% of TNBC patients experience recurrence or metastasis within five years of radiation and chemotherapy treatment.

Researchers at UCI have identified a protein found on cell surfaces called CUB-domain containing protein 1 (CDCP1). CDCP1 controls fat metabolism by lowering fat levels inside cells, thus causing more fatty acid oxidation (FAO), which has been linked to metastasis of TNBC. As a method to target cancer cells that lack hormone receptors, blocking fragment that inhibit CDCP1 activity have been developed. Specifically, the fragment blocks CDCP1 dimerization, reducing FAO. Reduction of FAO is accompanied with inhibition of tumor growth and reduced metastasis.

Suggested uses

Treatment for triple-negative breast cancer and other breast cancers

Advantages

  • Utilizes CDCP1 as a novel therapeutic target for treating breast cancer as opposed to hormone receptors
  • More effective at reducing tumor metastasis and preventing recurrence than generalized therapies (radiation, chemotherapy)

State Of Development

Efficacy of CDCP1 function-blocking has been shown in vitro and in vivo in two animal models of TNBC.

Related Materials

Contact

Learn About UC TechAlerts - Save Searches and receive new technology matches

Other Information

Categorized As

  • AN INTEGRAL PART OF
  • Institute for Innovation Logo
  • Institute for Innovation Logo

University of California, Irvine Invention Transfer Group
5141 California Avenue, Suite 200, Irvine,CA 92697-7700
Tel: 949.824.2683 | Fax: 949.824.3880
www.ota.uci.edu | ota@uci.edu

© 2018, The Regents of the University of California
Terms of use | Privacy Notice